158. 結節性硬化症 Tuberous sclerosis Clinical trials / Disease details
臨床試験数 : 112 / 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118
Showing 1 to 10 of 112 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05252585 (ClinicalTrials.gov) | April 23, 2023 | 16/2/2022 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis ... | Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese A ... | Renal Angiomyolipoma | Drug: Everolimus | Novartis Pharmaceuticals | NULL | Not yet recruiting | 20 Years | 65 Years | All | 10 | Phase 4 | NULL |
2 | NCT05495425 (ClinicalTrials.gov) | June 1, 2022 | 4/8/2022 | Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC | Placebo-controlled Comparative Study of NPC-12Y Gel in Patients With Skin Lesions Associated With Tuberous Sclerosis Complex Placebo-controlled Comparative Study of NPC-12Y Gel in Patients With Skin Lesions Associated With Tu ... | Tuberous Sclerosis Complex | Drug: NPC-12Y gel;Drug: NPC-12Y placebo gel | Nobelpharma | NULL | Recruiting | 3 Years | N/A | All | 40 | Phase 3 | Japan |
3 | NCT05604170 (ClinicalTrials.gov) | May 16, 2022 | 5/10/2022 | Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE) A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tub ... | Tuberous Sclerosis Complex | Drug: Ganaxolone | Marinus Pharmaceuticals | NULL | Enrolling by invitation | 1 Year | 65 Years | All | 169 | Phase 3 | United States |
4 | NCT05323734 (ClinicalTrials.gov) | April 1, 2022 | 21/3/2022 | Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy | A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC) A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatme ... | Tuberous Sclerosis Complex | Drug: Ganaxalone;Drug: Placebo | Marinus Pharmaceuticals | NULL | Recruiting | 1 Year | 65 Years | All | 162 | Phase 3 | United States;Canada;France;Germany;Israel;Italy;Spain;United Kingdom |
5 | ChiCTR2200055795 | 2022-02-01 | 2022-01-20 | Effect of ultrapulse carbon dioxide laser combined with photodynamic therapy on facial angiofibroma in tuberous sclerosis complex Effect of ultrapulse carbon dioxide laser combined with photodynamic therapy on facial angiofibroma ... | Effect of ultrapulse carbon dioxide laser combined with photodynamic therapy on facial angiofibroma in tuberous sclerosis complex Effect of ultrapulse carbon dioxide laser combined with photodynamic therapy on facial angiofibroma ... | tuberous sclerosis complex | Treatment Group:ultrapulse carbon dioxide laser combined with photodynamic therapy; | The First Hospital of Hebei Medical University | NULL | Pending | 6 | 60 | Both | Treatment Group:5; | China | |
6 | NCT05104983 (ClinicalTrials.gov) | October 13, 2021 | 22/10/2021 | Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Tuberous Sclerosis Complex;Epilepsy | Drug: Sirolimus;Drug: Placebo | Darcy Krueger | NULL | Recruiting | 1 Day | 6 Months | All | 64 | Phase 2 | United States |
7 | NCT05044819 (ClinicalTrials.gov) | July 7, 2021 | 30/8/2021 | Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol ... | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated Wi ... | Lennox Gastaut Syndrome;Dravet Syndrome;Tuberous Sclerosis Complex | Drug: Cannabidiol | Jazz Pharmaceuticals | NULL | Recruiting | 1 Year | N/A | All | 150 | Phase 4 | United States |
8 | NCT04485104 (ClinicalTrials.gov) | May 19, 2021 | 21/7/2020 | Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis ... | An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants With Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) Who Experience Inadequately-controlled Seizures An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive C ... | Seizure in Participants With Tuberous Sclerosis Complex;Seizure in Participants With Dravet Syndrome;Seizure in Participants With Lennox-Gastaut Syndrome Seizure in Participants With Tuberous Sclerosis Complex;Seizure in Participants With Dravet Syndrome ... | Drug: GWP42003-P | Jazz Pharmaceuticals | NULL | Recruiting | 1 Month | 23 Months | All | 27 | Phase 3 | United States |
9 | NCT04987463 (ClinicalTrials.gov) | May 7, 2021 | 28/5/2021 | Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis ComplexSy ... | Randomized, Placebo-controlled, Double-blind and Double-dummy Clinical Trial Comparing the Safety, Tolerability, and Efficacy of Vigabatrin and Rapamycin in a Preventive Treatment of Infants With Tuberous Sclerosis Complex Randomized, Placebo-controlled, Double-blind and Double-dummy Clinical Trial Comparing the Safety, T ... | Tuberous Sclerosis Complex | Drug: Vigabatrin;Drug: Rapamycin;Drug: Placebo | Katarzyna Kotulska | NULL | Recruiting | 4 Weeks | 16 Weeks | All | 60 | Phase 2/Phase 3 | Poland |
10 | NCT05059327 (ClinicalTrials.gov) | March 3, 2021 | 20/8/2021 | Basimglurant in Children, Adolescents, and Young Adults With TSC | A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-control ... | Tuberous Sclerosis Complex | Drug: Basimglurant with crossover to Placebo;Drug: Placebo with crossover to Basimglurant | Noema Pharma AG | NULL | Recruiting | 5 Years | 30 Years | All | 54 | Phase 2 | United States;Australia;India;Israel;Italy;Poland;Spain;Turkey;United Kingdom |